All In Biotech

Drug Trial Radar · NCT04037254

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

22

Actual

Start

Oct 8, 2019

Primary completion

Jul 1, 2024

Study completion Dec 23, 2025

Sponsor

Lead sponsor
NRG OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jul 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or returning. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding niraparib to the usual care may lower the chance of prostate cancer growing or returning.

Conditions

  • Prostate Adenocarcinoma
  • Stage IIC Prostate Cancer AJCC v8
  • Stage III Prostate Cancer AJCC v8
  • Stage IIIA Prostate Cancer AJCC v8
  • Stage IIIB Prostate Cancer AJCC v8
  • Stage IIIC Prostate Cancer AJCC v8
  • Stage IVA Prostate Cancer AJCC v8

Interventions

  • Gonadotrophin Releasing HormoneBiological

    Receive standard of care GnRH agonist androgen suppression therapy

  • Intensity-Modulated Radiation TherapyRadiation

    Undergo standard of care IMRT

  • NiraparibDrug

    tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Disease-free Until Completion of Treatment (2 Years From Start of ADT)Time frame: Baseline to completion of treatment (two years from start of ADT)

Locations

95 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • City of Hope Upland

    Upland, California

  • Helen F Graham Cancer Center

    Newark, Delaware

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware

  • George Washington University Medical Center

    Washington D.C., District of Columbia

  • Grady Health System

    Atlanta, Georgia

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia

  • CTCA at Southeastern Regional Medical Center

    Newnan, Georgia

  • Alton Memorial Hospital

    Alton, Illinois

  • Northwestern University

    Chicago, Illinois

  • Rush MD Anderson Cancer Center

    Chicago, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • University of Iowa/Holden Comprehensive Cancer Center

    Iowa City, Iowa

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • University of Kansas Cancer Center-Overland Park

    Overland Park, Kansas

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland

  • Central Maryland Radiation Oncology in Howard County

    Columbia, Maryland

  • UM Baltimore Washington Medical Center/Tate Cancer Center

    Glen Burnie, Maryland

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • McLaren Cancer Institute-Bay City

    Bay City, Michigan

  • Henry Ford Cancer Institute-Downriver

    Brownstown, Michigan

  • McLaren Cancer Institute-Clarkston

    Clarkston, Michigan

  • Henry Ford Macomb Hospital-Clinton Township

    Clinton Township, Michigan

  • Henry Ford Medical Center-Fairlane

    Dearborn, Michigan

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan

  • McLaren Cancer Institute-Flint

    Flint, Michigan

  • Singh and Arora Hematology Oncology PC

    Flint, Michigan

  • Karmanos Cancer Institute at McLaren Greater Lansing

    Lansing, Michigan

  • Mid-Michigan Physicians-Lansing

    Lansing, Michigan

  • McLaren Cancer Institute-Lapeer Region

    Lapeer, Michigan

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.